Predictive factors for outcomes after reduced intensity conditioning hematopoietic stem cell transplantation for hematological malignancies:: A 10-year retrospective analysis from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

被引:51
作者
Michallet, Mauricette [2 ]
Le, Quoc-Hung [2 ]
Mohty, Mohamad [1 ]
Prebet, Thomas [2 ]
Nicolini, Franck [2 ]
Boiron, Jean Michel [3 ]
Esperou, Helene [4 ]
Attal, Michel [5 ]
Milpied, Noel [1 ]
Lioure, Bruno [6 ]
Bordigoni, Pierre [7 ]
Yakoub-Agha, Ibrahim [8 ]
Bourhis, Jean-Henri [9 ]
Rio, Bernard [10 ]
Deconinck, Eric [11 ]
Renaud, Marc [12 ]
Chir, Zina [13 ]
Blaise, Didier [14 ]
机构
[1] CHU Nantes, Hop Hotel Dieu, F-44035 Nantes 01, France
[2] Hop Edouard Herriot, Serv Hematol, Lyon, France
[3] Hop Pessac, Serv Hematol, Bordeaux, France
[4] Hop St Louis, Unite Greffe Moelle Osseuse, Paris, France
[5] Hop Purpan, Serv Hematol, Toulouse, France
[6] Hop Hautepierre, Serv Hematol, Strasbourg, France
[7] Hop Nancy, Serv Hematol, Nancy, France
[8] Hop Huriez, Serv Hematol, Lille, France
[9] Inst Gustave Roussy, Serv Hematol, Villejuif, France
[10] Hop Hotel Dieu, Serv Hematol, F-75181 Paris, France
[11] Hop Besancon, Serv Hematol, Besancon, France
[12] Hop Poitiers, Serv Hematol, Poitiers, France
[13] Agence Biomed, SFGM TC, Paris, France
[14] Inst J Paoli I Calmettes, F-13009 Marseille, France
关键词
D O I
10.1016/j.exphem.2008.01.017
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This retrospective study analyzed the impact of demographic and transplantation variables on outcomes of 1108 patients who have undergone allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning (RIC HSCT) for hematological malignancies and were reported to the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire registry between November 1994 and December 2004. Only 442 patients (40%) were in complete remission (CR) at time of transplantation. Peripheral blood stem cells were used in the majority of patients (n = 878; 79%), 255 patients received fludarabine and low-dose total body irradiation, while 465 patients (42%) fludarabine and busulfan with rabbit anti-thymocyte globulins (ATG). The impact of demographic and transplant variables was studied on overall (OS) and event-free survival (EFS) in univariate and multivariate analysis. With a median follow-up of 21 months, 3-year probability of OS and EFS was 42% and 30%, respectively, and treatment-related mortality was 15% at 2 years. The multivariate analysis showed a significant negative impact on OS and EFS of the absence of CR status before transplantation; conditioning regimen, including > 10 mg/kg ATG; and minor ABO incompatibility. In conclusion, this study highlights the major impact on RIC HSCT outcome of disease status before transplantation, ATG dose and ABO incompatibility. (C) 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc.
引用
收藏
页码:535 / 544
页数:10
相关论文
共 44 条
[1]   Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies [J].
Alessandrino, EP ;
Bernasconi, P ;
Colombo, AA ;
Caldera, D ;
Malcovati, L ;
Troletti, D ;
Vanelli, L ;
Varettoni, M ;
Montanari, F ;
Lazzarino, M .
BONE MARROW TRANSPLANTATION, 2004, 34 (12) :1039-1045
[2]   Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age [J].
Alyea, EP ;
Kim, HT ;
Ho, V ;
Cutler, C ;
Gribben, J ;
DeAngelo, DJ ;
Lee, SJ ;
Windawi, S ;
Ritz, J ;
Stone, RM ;
Antin, JH ;
Soiffer, RJ .
BLOOD, 2005, 105 (04) :1810-1814
[3]  
ATKINSON K, 1990, BLOOD, V75, P2459
[4]   Antithymocyte globulin for prevention of graft-versus-host disease [J].
Bacigalupo, A .
CURRENT OPINION IN HEMATOLOGY, 2005, 12 (06) :457-462
[5]  
Bacigalupo A, 2004, BONE MARROW TRANSPL, V33, pS29, DOI 10.1038/sj.bmt.1704416
[6]   Improving outcome of allogeneic stem cell transplantation by immunomodulation of the early post-transplant environment [J].
Barrett, John .
CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (05) :592-598
[7]   Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia [J].
Blaise, Didier ;
Vey, Norbert ;
Faucher, Catherine ;
Mohty, Mohamad .
HAEMATOLOGICA, 2007, 92 (04) :533-541
[8]   Long-term follow-up of high-risk allogeneic peripheral-blood stem-cell transplant recipients: Graft-versus-host disease and transplant-related mortality [J].
Brown, RA ;
Adkins, D ;
Khoury, H ;
Vij, R ;
Goodnough, LT ;
Shenoy, S ;
DiPersio, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :806-812
[9]   Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma [J].
Carella, AM ;
Cavaliere, M ;
Lerma, E ;
Ferrara, R ;
Tedeschi, L ;
Romanelli, A ;
Vinci, M ;
Pinotti, G ;
Lambelet, P ;
Loni, C ;
Verdiani, S ;
De Stefano, F ;
Valbonesi, M ;
Corsetti, MT .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (23) :3918-3924
[10]   Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].
Childs, R ;
Chernoff, A ;
Contentin, N ;
Bahceci, E ;
Schrump, D ;
Leitman, S ;
Read, EJ ;
Tisdale, J ;
Dunbar, C ;
Linehan, WM ;
Young, NS ;
Barrett, AJ ;
Clave, E ;
Epperson, D ;
Mayo, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758